Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMG1U5K)

Drug Name
Rocatinlimab Drug Info
Synonyms AMG 451 / KHK4083
Indication
Disease Entry ICD 11 Status REF
Atopic dermatitis EA80 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMG1U5K

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
OX40L receptor (CD134) TTL31H0 TNR4_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
OX40L receptor (CD134) DTT TNFRSF4 3.413 3.018 2.104 2.888
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Atopic dermatitis
ICD Disease Classification EA80
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
OX40L receptor (CD134) DTT TNFRSF4 2.17E-06 1.01 1.66
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT05633355) A Phase 3, Open-label, 52-week Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab (AMG 451) in Adolescent Subjects Aged >= 12 to < 18 Years With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit). U.S.National Institutes of Health.
2 An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Lancet. 2023 Jan 21;401(10372):204-214.